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Orexins have previously been shown to promote wakefulness, regulate lipid metabolism and participate in energy homeostasis.
The aim of the study was to determine the relationship between plasma orexin-A and body composition in COPD in-patients
with hypercapnic respiratory failure. 40 patients with hypercapnic respiratory failure and 22 healthy individuals were enrolled
prospectively in this study. Plasma orexin-A levels, BMI, SaO2,P a C O 2 and PaO2 were noted for all the patients. Plasma orexin-A
levels were higher in the underweight (UW) group, normal weight (NW) group and overweight (OW) group of COPD patients
as compared with UW, NW and OW group of the control group (P<. 05). Plasma orexin-A in COPD patients were higher in
the OW group than in the NW group and the UW group. Plasma orexin-A levels showed signiﬁcant correlation with body mass
index (BMI), independent of PaO2 (r = 0.576; P<. 05) and %fat (r = 0.367; P<. 05); a negative correlation was noted between
plasma orexin-A levels and PaO2 (r =− 0.738; P<. 05) and SaO2 (r =− 0.616; P<. 05). Our results suggest that orexin-A levels
are high in COPD patients with hypercapnic respiratory failure, and vary according to BMI and body composition.Orexin-A may
be associated with the severity of hypoxemia in COPD patients with hypercapnic respiratory failure.
1.Introduction
Body weight is an important prognostic factor of chronic
obstructivepulmonary disease in thata low body weight cor-
relates with increased morbidity and poor prognosis [1–3].
This is mainly because a low body weight in COPD patients
implies weakening of both respiratory muscles and skeletal
muscles [4, 5]. The weakening of respiratory muscles, in
turn, makes COPD patients vulnerable to respiratory failure.
It is widely known that COPD is one of the main causes
of acute respiratory failure. Resting hypoxia, usually due to
VA/Q mismatching, and exercise aggravation of hypoxia due
t oincr eas edﬂo wando xygendis equilibriumareoftenseenin
COPD patients [6, 7]. Acute hypercapnic respiratory failure
as a result of an acute exacerbation of COPD is a common
reason for emergency hospital admission [8]. It has been
noted that an acute exacerbation of COPD entails decreased
food intake and increased resting energy expenditure, thus
causing energy disbalance in these patients [9].
Orexin-A and orexin-B belong to the family of orexins
are neuropeptides identiﬁed within the lateral hypothalamus
during the last decade [10]. Previous studies show that
intraventricular injection of orexin-A not only produces a
dose-dependent food intake but also increases the metabolic
rate [10, 11]. Apart from promoting wakefulness and
regulating lipidmetabolism, orexin-A has been implicatedin
diabetes mellitus and obesity [12–14]. In 2003, Matsumura
et al. successfully showed that plasma orexin-A levels are
lower in COPD patients, with a lower level being more
prominent in underweight patients as compared to normal
individuals [15]. However, whether plasma orexin-A levels
show the same variation in COPD patients with hypercapnic
respiratory failure has not been investigated. We therefore
tried to assess plasma orexin-A levels during an acute
exacerbation of COPD.
2.Materialsand Methods
2.1. Subjects. Forty COPD patients with hypercapnic res-
piratory failure who were hospitalized in the Department
of Pulmonary Medicine of Zhongshan Hospital, Shanghai,
were included in the study. The diagnosis of COPD was2 Mediators of Inﬂammation
based on past smoking history, clinical evaluation, and
pulmonary function tests according to the American Tho-
racic Society Guidelines [16]. All the 40 patients had an
arterial partial pressure of CO2 (PaCO2)o f≥50mmHg,
which is line with hypercapnic respiratory failure diagnosis.
Patients with a history of use of systemic corticosteroids
or with a history of sleep-related breathing disorders,
malignancy, cardiac failure, diabetes mellitus, or other
endocrine diseases were excluded. The control group con-
sisted of 22 healthy individuals, without any underlying
disease and with normal pulmonary function as deﬁned
by (FEV1/FVC > 70%) who presented to the Zhongshan
Hospital for routine physical examination. The research
protocol was approved by the Ethics Committee of Fudan
University, and written consent form was obtained for each
subject.
2.2. Nutritional Assessment. The following parameters were
recorded for each patient: age (in years), body weight (in
kilograms), and height (in meters). Based on these measures,
body mass index (BMI) and body fat percentage were
calculated. BMI was calculated as weight/(height)2.B o d yf a t
% was calculated as follows: male = (1.2 × BMI) + (0.23 ×
age) − 16.2, and female = (1.2 × BMI) + (0.23 × age) −
5.4.
Based in their BMI, the control group subjects and the
patients with COPD were further subdivided into 3 groups:
(1)underweight (UW)group(BMI<20),(2)normal weight
(NW) group (20 ≤ BMI < 25), and (3) overweight (OW)
group (BMI ≥ 25).
2.3. Samples. 4mL blood samples were collected from the
antecubital vein by using a vacuum blood-collecting tube
containing aprotinin at noon. Plasma, separated by centrifu-
gation, was stored at −80◦C until analysis. Orexin-A concen-
trations were always measured in duplicate in the following
way: plasma orexin-A was ﬁrst extracted using extraction
columns (Extra-Sep C18, Lida, Kenosha, Wisc., USA). Then,
column eluants were evaporated to dryness in a centrifugal
concentrator and reconstituted in radioimmunoassay buﬀer.
Finally, orexin-A levels in the reconstituted aliquots were
determined using an iodine-125 hypocretin-1 RIA system
(Phoenix Pharmaceuticals, Mountain View, Calif, USA).
Mean values of orexin-A were calculated and used for
statistical analysis.
Arterial blood was drawn from all subjects during room
air breathing at the same time that blood was collected for
orexin-A level measurement.
2.4. Statistical Analysis. The Mann-Whitney U-test and
ANOVA were used to analyze the diﬀerence between two
groups. Spearman’s rank correlation technique and partial
correlation technique were used to analyze the relationship
between several continuous variables. Results are expressed
as medians [range] or mean ± SE as appropriate. Statistical
analysis was performed using a statistical software package
(SPSS 13.0); P<. 05 was considered to be statistically
signiﬁcant.
Table 1: Baseline characteristics of subjects.
Group n Age (years) BMI (kg/m2)
Control subjects
UW 5 73.8 ±11.91 9 .2 ± 0.9
NW 14 72.6 ±10.42 2 .0 ± 1.1
OW 3 74.0 ±8.72 8 .5 ± 2.4
COPD
UW 10 76.2 ±5.01 8 .3 ± 1.2
NW 23 73.2 ±10.42 1 .7 ± 1.4
OW 7 74.7 ±7.02 6 .2 ± 0.9
Table 2: Plasma orexin-A levels in weight-based group.
Control subjects Patients with COPD
n orexin-A (pg/mL) n orexin-A (pg/mL) P
median range median range
UW 5 9.00 8.00–18.69 10 36.32 22.71–44.88 .000
NW 14 15.44 5.96–33.61 23 48.51 14.55–95.86 .000
OW 3 20.55 10.18–23.62 7 56.00 45.26–101.26 .001
3.Results
3.1. Subject Characteristics. Out of the 40 patients with
COPD, 32 were male and 8 were female. The mean age of the
subjects was (74.2±8.7 )y e a r sa n dt h em e a nB M Iw a s( 2 1 .7±
3.0)kg/m2. Out of the 22 control subjects, 17 were male and
5 were female. The mean age was (73.1 ± 10.1) years and the
mean BMI was (22.3 ± 3.0)kg/m2. The mean age and the
mean BMI of COPD patients and control subjects belonging
to the UW, NW, and OW groups are shown in Table 1.T h e r e
was no statistical diﬀerence in the baseline characteristics
(age and BMI) between the patients with COPD and the
control subjects.
3.2. Plasma Orexin-A Levels. Plasma orexin-A levels in each
group of COPD patients and control subjects are shown
in Table 2. UW, NW, and OW patients with COPD had
signiﬁcantly higher plasma orexin-A levels as compared to
UW, NW, and OW control subjects (P<. 000, P<. 000, and
P<. 001, resp.).
3.3. Relationship between Diﬀerent Observed Indexes of COPD
Patients and Control Subjects and Plasma Orexin-A Levels.
Plasma orexin-A levels in COPD patients were found to
correlate signiﬁcantly with BMI (r = 0.589, P = .000)
(Figure 1(a)), %fat (r = 0.367, P = .020) (Figure 1(b)),
PaO2 (r =− 0.738, P = .000) (Figure 1(c)), and SaO2 (r =
−0.616, P = .000) (Figure 1(d)). Partial correlation analysis
was used to determine whether the correlation between
plasma orexin-A and BMI was independent of the degree of
respiratory failure, and, controlling PaO2,p l a s m ao r e x i n - A
was still found tocorrelate signiﬁcantly with BMI(r = 0.576,
P = .000). However, no correlation was found between
PaCO2 and plasma orexin-A levels (P = .173).
Plasma orexin-A levels in control subjects were found to
correlate signiﬁcantly with BMI (r = 0.428, P = .047).Mediators of Inﬂammation 3
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Figure 1: (a) Relationship between BMI and orexin-A. (b) Relationship between %fat and orexin-A. (c) Relationship between PaO2 and
orexin-A. (d) Relationship between SaO2 and orexin-A. In patients with COPD, plasma orexin-A levels signiﬁcantly correlated with BMI
(r = 0.589, P = .000), %fat (r = 0.367, P = .020),PaO2 (r =− 0.738, P = .000), SaO2 (r =− 0.616, P = .000).
4.Discussion
Orexin, also known as hypocretin, was ﬁrst described in
1998 by de Lecea et al. [17]. In 1999, orexin neurons were
found to be present in the lateral hypothalamic area, peri-
fornical nucleus, diﬀuse part of the dorsomedial hypo-
thalamic nucleus, and posterior hypothalamus [18]. It has
been previously shown that orexins can pass the blood-
brain barrier by simple diﬀusion [19] and that orexins and
orexins receptors are present in the hypothalamus as well
as the enteric nervous system, adipose tissue, the pancreas
and the gut [20, 21]. Orexin not only acts as an appetite
stimulator but also acts along with other neuropeptides to
regulate feeding behavior [22, 23].
Our results show that plasma orexin-A levels in COPD
patients with hypercapnic respiratory failure are much
higher than those in normal subjects. These results diﬀer
from those of Matsumura et al. [15]. We can explain the
discrepancies in our results by the fact that our study
included a larger number of patients and our patients were
all hospitalized COPD patients with hypercapnic respiratory
failure while those of Matsumura et al. were outpatients,
without any exacerbation of COPD. COPD patients with
hypercapnic respiratory failure have a larger amount of
energy expenditure and have decreased food intake as
compared to COPD patients who are not suﬀering from an
acute disease exacerbation. This energy imbalance may well
be another plausible explanation for the higher values of4 Mediators of Inﬂammation
plasma orexin-A in COPD patients in our study. Due to the
fact that COPD patients with hypercapnic respiratory failure
restricted food intake, there is subsequently an increase in
the expression of prepro-orexin gene [24], which in turn
causes an increase in the plasma orexin-A levels noted in our
patients.
Patients from the OW group were found to have higher
plasma orexin-A levels than those from the NW group, who
in turn, had higher plasma orexin-A levels than those of the
UWgroup.Wefurtherfoundthatplasmaorexin-Alevelsand
BMI were correlated and the correlation was independent
of the degree of respiratory failure. These results are in
concordance with those of Matsumura et al. Other previous
studies have shown that plasma orexin-A levels correlate
with BMI [25, 26]. However, Adam et al. found that plasma
orexin-A was lower in obese individuals [27]. These diﬀerent
results might well be explained by the fact that plasma
orexin-A levels might be dependent on the underlying
d i s e a s ef r o mw h i c ht h ep a t i e n t sa r es u ﬀering from. In our
present study, we also found a positive correlation between
plasma orexin-A levels and %fat in COPD patients with
hypercapnic respiratory failure. In 2002, Wortley et al.
showed that circulating lipids increase in obesity and the
increase in triglyceride levels increase hypothalamic orexin
geneexpression inrats [28].In2006,Digbyetal. showed that
orexin receptors are found in adipose tissue and that orexins
may play a role in adipogenesis [21]. Therefore, our results
are in concordance with these ﬁndings.
Orexin participates in respiratory control by increasing
ventilation [29]. Dreshaj et al. showed that lesions in the
basomedial hypothalamus have been found to inﬂuence
respiratory response in neonatal rats in that the latter show
impaired response to hypoxia. However, these lesions did
not aﬀect the hypercapnic responses [30]. On the other
hand, Deng et al. showed that orexin knock-out mice had
weakened respiratory chemoreﬂex to hypercapnic gases, but
not to hypoxic gases [31]. In our study, we found no
correlation between plasma orexin-A levels and PaCO2;b u t ,
a signiﬁcant negative correlation was noted between plasma
orexin-A levels and PaO2 and SaO2. Similar ﬁndings have
been formerly noted [32]. Our results indicate that orexin-
A may play an important part during hypoxia; however, the
underlying mechanism remains to be revealed.
Here we must point out that there are several limitations
to our study. Firstly, we included a limited number of
patients. Although plasma orexin-A levels in COPD patients
were found to correlate signiﬁcantly with BMI, %fat, PaO2
and SaO2, the results for individual COPD patients were in
fact, quite variable, and therefore, studies including larger
number ofpatientsshould be carried out inorderto conﬁrm
our results. Moreover, in our study we did not study the
mechanism through which orexin-A is upregulated during
hypoxia.
5.Conclusions
This study shows that plasma orexin-A levels correlate
with BMI and %fat in COPD patients with hypercapnic
respiratory failure and that orexin-A levels may be altered
during hypoxia, and more studies are required to determine
the role of orexin-A in hypoxia.
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